Soleno Therapeutics to Participate in Upcoming September Conferences

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September:

Cantor Global Healthcare Conference Presentation Date: Wednesday, September 3, 2025 at 1:00 PM ET Presentation Format: Fireside Chat Webcast: Here

Wells Fargo Healthcare Conference Presentation Date: Thursday, September 4, 2025 at 1:30 PM ET Presentation Format: Fireside Chat Webcast: Here

H.C. Wainwright 27 th Annual Global Investment Conference Presentation Date: Monday, September 8, 2025 at 4:00 PM ET Presentation Format: Fireside Chat

Baird Global Healthcare Conference Presentation Date: Tuesday, September 9, 2025 at 2:00 PM ET Presentation Format: Fireside Chat

Bernstein 2 nd Annual Healthcare Forum Presentation Date: Thursday, September 25, 2025 at 9:40 AM ET Presentation Format: Fireside Chat

Replays of the Cantor and Wells Fargo events will be available in the Investors section on the Company’s website at www.soleno.life .

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life .

Corporate Contact: Brian Ritchie LifeSci Advisors, LLC 212-915-2578